within Pharmacolibrary.Drugs.ATC.A;

model A10BD28
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.55,
    Cl             = 75 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,
    adminCount     = 1,
    Vd             = 0.06,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0010333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Metformin and teneligliptin is a fixed dose combination of two antidiabetic agents: metformin, a biguanide that reduces hepatic glucose production and increases insulin sensitivity, and teneligliptin, a DPP-4 inhibitor that increases incretin levels and glucose-dependent insulin secretion. This combination is approved and widely used for the treatment of type 2 diabetes mellitus in adults to improve glycemic control.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for typical adult population receiving the fixed-dose combination orally. No primary published population pharmacokinetic (PopPK) models for the combination product found; parameters are based on known monotherapy PK data and fixed dose combination prescribing information.</p><h4>References</h4><ol><li><p>Scott, LJ (2015). Teneligliptin: a review in type 2 diabetes. <i>Clinical drug investigation</i> 35(11) 765–772. DOI:<a href=&quot;https://doi.org/10.1007/s40261-015-0348-9&quot;>10.1007/s40261-015-0348-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26475720/&quot;>https://pubmed.ncbi.nlm.nih.gov/26475720</a></p></li><li><p>Deacon, CF, &amp; Lebovitz, HE (2016). Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. <i>Diabetes, obesity &amp; metabolism</i> 18(4) 333–347. DOI:<a href=&quot;https://doi.org/10.1111/dom.12610&quot;>10.1111/dom.12610</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26597596/&quot;>https://pubmed.ncbi.nlm.nih.gov/26597596</a></p></li><li><p>Chen, XW, et al., &amp; Zhou, SF (2015). Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. <i>Clinical and experimental pharmacology &amp; physiology</i> 42(10) 999–1024. DOI:<a href=&quot;https://doi.org/10.1111/1440-1681.12455&quot;>10.1111/1440-1681.12455</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26173919/&quot;>https://pubmed.ncbi.nlm.nih.gov/26173919</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BD28;
